Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer

Nasopharyngeal carcinoma (NPC) occurs worldwide with approximately 87,000 incident cases and 51,000 deaths annually, representing about 0.7% of the global cancer burden [1]. A distinct racial and geographical variation is evident with a higher incidence rate in both southern China and Southeast Asia. This geographic predisposition is suggestive of both genetic and environmental risk factors in its pathogenesis. For instance, several at risk HLA genes such as the HLA-A subtype; and exposure to nitrosamines and nitrosamine precursors in the diet have been reported as risk factors of developing NPC.
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research